A method of modulating KAT6A in a subject comprising administering to the subject in need thereof, a therapeutically effective amount of compound according to any one of claims 1 to 52 or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.
56. A method of treating a disease or disorder mediated by KAT6A in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 52 or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.
57. The method of claim 56, wherein the disease or disorder is cancer. 58. The method of claim 57, wherein the cancer is selected from brain gliomas, glioblastomas, astrocytomas, multiforme, bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast cancer, colon cancer, head and neck cancer, kidney, liver, lung cancer, bone cancer, colorectal cancer, germ cell cancer, melanoma, ovarian cancer, pancreatic cancer, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid cancer, lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, mantle cell leukemia, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphoblastic T cell lymphoma, Burkitt’s lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, uterine/cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharyngeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers, testicular cancer and virus-related
cancer.
59. Compound according to any one of claims 1 to 41 for use in the treatment of a disease or disorder mediated by KAT6A.